Irlanda - inglés - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - estradiol dydrogesterone - film coated tablet - 0.5/2.5 milligram

Malta - inglés - Medicines Authority

bgp products ltd - dydrogesterone 2.5 mg, estradiol 0.5 mg - film-coated tablet

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - estradiol dydrogesterone - film coated tablet - 1mg/5mg milligram

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

bgp products ltd - estradiol, dydrogesterone - film coated tablet - 1mg/5mg milligram - progestogens and estrogens, fixed combinations - : genito urinary system and sex hormones, progestogens and oestrogens, fixed combinations - hormone replacement therapy (hrt) for oestrogen deficiency symptoms in postmenopausal women at least 12 months since last menses. prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

bgp products ltd - estradiol, dydrogesterone - film coated tablet - 0.5/2.5 milligram - progestogens and estrogens, fixed combinations

Australia - inglés - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Australia - inglés - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - dydrogesterone, quantity: 10 mg; estradiol, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; colloidal anhydrous silica; lactose monohydrate; maize starch; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - estradiol hemihydrate dydrogesterone - film coated tablet - 1 mg, 10 m milligram

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

abbott healthcare products ltd - estradiol hemihydrate dydrogesterone - film coated tablet - 2 mg, 10 m milligram

Singapur - inglés - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - dydrogesterone, micronized (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) - tablet, film coated - 10 mg - dydrogesterone, micronized (in grey tablet) 10 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet) 1 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) 1 mg